PTC THERAPEUTICS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
Mailing Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
Phone
9082227000
Fiscal Year End
1231
EIN
043416587
Financial Overview
FY2025
$984.65M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 26, 2026 | View on SEC |
| 3 Initial insider ownership report | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | February 23, 2026 | View on SEC |
Annual Reports
10-K
February 19, 2026
- Robust revenue growth: $1.1 billion in 2024, a 15.8% increase, with a projected $1.25 billion for 2025.
- Improved net loss of $150 million in 2024, an improvement from $200 million in 2023, reflecting strong R&D investment.
Material Events
8-K
Strategy Change
February 12, 2026
High Impact
- PTC Therapeutics officially withdrew its New Drug Application (NDA) resubmission for Translarna™ (ataluren) in the U.S. for nonsense mutation Duchenne muscular dystrophy (nmDMD).
- Translarna continues to hold conditional approval and generate revenue in Europe and other international regions.
Insider Trading
STRONG SELL
10 insiders
82 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.